Skip to content

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis: A Double Blinded Randomized Prospective Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01346059
Enrollment
2
Registered
2011-05-02
Start date
2011-04-30
Completion date
2012-02-29
Last updated
2017-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colitis

Keywords

Clostridium, Colitis, Intracolonic vancomycin, psuedomembranous colitis

Brief summary

Clostridium difficile is a bacteria that can infect the colon and cause severe diarrhea in patients after recent antibiotic use. The current standard of care treatment for severe C. diff. consists of oral vancomycin and/or intravenous metronidazole. When treatment is unsuccessful, it can lead to need for removal of the entire colon or even death. In fact, mortality rates in the literature range from 11-37% for C. diff. The most commonly quoted mortality rate is 14% for severe infection. It is believed that the failure of treatment may stem from an adynamic ileus (paralysis of the small bowel). This ileus may prevent the oral vancomycin from reaching the colon and therefore it does not treat the problem. Vancomycin functions by direct contact with the colon. Therefore, if the vancomycin is instilled directly into the colon, it can come into contact with and be its intended target. : The objective of the study is to improve treatment of severe C. diff. colitis . C. diff. infection is defined as severe if there is evidence of ileus accompanied by any one of the following: fever greater than 38.30C, , acidemia, serum albumin less than 2.5, or white blood cell count greater than 14,000.

Detailed description

Patients in the surgical intensive care unit with severe C. diff. are eligible and if consented will be randomized in a 1:1 ratio to a control group or the treatment group. Each group will undergo a colonoscopy on day one of the study. A 14 French Cook colonic decompression catheter will be placed at that time. This catheter is a 175cm long soft flexible catheter designed to be placed in the colon. Its usual use is to remove air from a colon that is dilated. The catheter is placed into the colon by first placing a guidewire through the colonoscope. The colonoscope is then removed leaving the guidewire in place. The catheter is then thread into the colon over the guidewire. An xray is obtained to confirm the location of the catheter and then the guidewire is removed. The guidewire is a very thin, soft, flexible wire. The patient will not have any undue discomfort secondary to the catheter. The control group will have 250cc of sterile saline solution instilled through the catheter into the colon every 6 hours. The study group will have 250cc of vancomycin solution instilled every 6 hours. The solution will be 2 grams vancomycin dissolved in a 1 liter normal saline irrigation bottle. The catheter will be clamped in both groups after instillation until the next treatment. Of note, both groups will receive the current standard treatment of 500mg IV metronidazole every 8 hours and 250mg oral vancomycin every 6 hours throughout the study. Every day the patients will have a blood draw to check the white blood cell count as is the current practice. The patients will also have a vancomycin trough level checked via blood test. This will occur just prior to the first dosing on treatment day number 3. This will be a blinded lab value as to not unblind the investigators. At resolution Patients will undergo a repeat colonoscopy when there is a decrease of diarrhea (less than 3 stools daily) and a normalized white blood cell count or on day 7 if symptoms persist. The expected length of treatment is approximately 7 days. If there is no improvement at fourteen days, the trial will be stopped for futility. The trial will also be halted if the attending physician determines that the patient needs surgery or if the clinical status of the patient has deteriorated to a point where keeping the patient enrolled will potentially cause harm. Follow-up after completing the trial will consist of phone interviews to screen for recurrence of infection. A weekly phone call will be made for the first three weeks and then two monthly calls will take place after that for a total of three months follow-up. The primary investigator will make these phone calls.

Interventions

DRUGVancomycin

Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.

DRUGSaline

Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.

Sponsors

Corewell Health East
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* SICU patient * positive c. diff toxin assay * visualization of pseudomembranes on colonoscopy, * able to give consent or have representative to give consent.

Exclusion criteria

* Under age 18 * pregnant * absence of a colon or surgical discontinuity of bowel * allergy to vancomycin * need for anti-diarrheal medication * need for prolonged antibiotics for other cause * need for probiotics * need for other medications with action against C. diff. * need for surgery, colon perforation * recent IV IG use * toxic megacolon.

Design outcomes

Primary

MeasureTime frameDescription
Resolution of Diarrhea and White Blood Cell Count Elevation14 daysIf the patient has resolution of diarrhea, white blood cell count, and abdominal pain, the protocol will be stopped.

Secondary

MeasureTime frameDescription
Mortality30 dayDeath within 30 days of enrollment, in or out of hospital
Need for Colectomy30 dayPartial or complete colectomy performed within 30 days of enrollment

Countries

United States

Participant flow

Pre-assignment details

All patients enrolled undergo a complete colonoscopy with placement of a 14 French colon decompression catheter (Cook Medical). Proper placement of the catheter in the cecum is verified by abdominal X-ray. Patients are randomized to either Saline or Vancomycin arms.

Participants by arm

ArmCount
Saline
The saline arm will receive normal saline through the catheter as a placebo. Saline: Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
1
Vancomycin
The vancomycin arm will receive vancomycin solution through the catheter. Vancomycin: Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
1
Total2

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicSalineVancomycinTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants1 Participants2 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Region of Enrollment
United States
1 participants1 participants2 participants
Sex: Female, Male
Female
1 Participants1 Participants2 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 10 / 1
other
Total, other adverse events
0 / 10 / 1
serious
Total, serious adverse events
0 / 10 / 1

Outcome results

Primary

Resolution of Diarrhea and White Blood Cell Count Elevation

If the patient has resolution of diarrhea, white blood cell count, and abdominal pain, the protocol will be stopped.

Time frame: 14 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
VancomycinResolution of Diarrhea and White Blood Cell Count Elevation1 Participants
Secondary

Mortality

Death within 30 days of enrollment, in or out of hospital

Time frame: 30 day

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
VancomycinMortality0 Participants
Secondary

Need for Colectomy

Partial or complete colectomy performed within 30 days of enrollment

Time frame: 30 day

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
VancomycinNeed for Colectomy0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026